222 related articles for article (PubMed ID: 27175586)
21. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Kim JJ; Vaziri SA; Rini BI; Elson P; Garcia JA; Wirka R; Dreicer R; Ganapathi MK; Ganapathi R
Cancer; 2012 Apr; 118(7):1946-54. PubMed ID: 21882181
[TBL] [Abstract][Full Text] [Related]
22. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
[TBL] [Abstract][Full Text] [Related]
24. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Hess G; Borker R; Fonseca E
Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
[TBL] [Abstract][Full Text] [Related]
25. [Angiogenesis targeting in renal carcinomas].
Pouessel D; Culine S
Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA; Eechoute K; Gelderblom H; Gietema J; Guchelaar HJ; van Erp NP; van den Eertwegh AJ; Haanen JB; Mathijssen RH; Wessels JA
Clin Cancer Res; 2011 Feb; 17(3):620-9. PubMed ID: 21097692
[TBL] [Abstract][Full Text] [Related]
27. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
[TBL] [Abstract][Full Text] [Related]
28. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
Tannir NM; Msaouel P; Ross JA; Devine CE; Chandramohan A; Gonzalez GMN; Wang X; Wang J; Corn PG; Lim ZD; Pruitt L; Karam JA; Wood CG; Zurita AJ
Eur Urol Oncol; 2020 Oct; 3(5):687-694. PubMed ID: 31272939
[TBL] [Abstract][Full Text] [Related]
29. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
[TBL] [Abstract][Full Text] [Related]
30. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
Paule B; Bastien L; Deslandes E; Cussenot O; Podgorniak MP; Allory Y; Naïmi B; Porcher R; de La Taille A; Menashi S; Calvo F; Mourah S
PLoS One; 2010 May; 5(5):e10715. PubMed ID: 20502715
[TBL] [Abstract][Full Text] [Related]
31. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.
Villa G; Hernández-Pastor LJ
BMC Cancer; 2013 Sep; 13():399. PubMed ID: 24004638
[TBL] [Abstract][Full Text] [Related]
32. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
33. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Yuasa T; Takahashi S; Hatake K; Yonese J; Fukui I
Cancer Sci; 2011 Nov; 102(11):1949-57. PubMed ID: 21812860
[TBL] [Abstract][Full Text] [Related]
35. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
D' Alterio C; Portella L; Ottaiano A; Rizzo M; Carteni G; Pignata S; Facchini G; Perdona S; Di Lorenzo G; Autorino R; Franco R; La Mura A; Nappi O; Castello G; Scala S
Curr Cancer Drug Targets; 2012 Jul; 12(6):693-702. PubMed ID: 22463589
[TBL] [Abstract][Full Text] [Related]
36. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
Matrana MR; Duran C; Shetty A; Xiao L; Atkinson BJ; Corn P; Pagliaro LC; Millikan RE; Charnsangave C; Jonasch E; Tannir NM
Eur J Cancer; 2013 Oct; 49(15):3169-75. PubMed ID: 23810246
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.
Keizman D; Huang P; Eisenberger MA; Pili R; Kim JJ; Antonarakis ES; Hammers H; Carducci MA
Eur J Cancer; 2011 Sep; 47(13):1955-61. PubMed ID: 21600760
[TBL] [Abstract][Full Text] [Related]
39. Kidney cancer: Comparing first-line treatments for mRCC.
Phillips R
Nat Rev Urol; 2013 Oct; 10(10):557. PubMed ID: 24018564
[No Abstract] [Full Text] [Related]
40. Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Vasudev NS; Goh V; Juttla JK; Thompson VL; Larkin JM; Gore M; Nathan PD; Reynolds AR
Br J Cancer; 2013 Sep; 109(5):1230-42. PubMed ID: 23922108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
